[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579369":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":22,"responsibleParty":52,"collaborators":7,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":7,"enrollmentInfo":64,"targetDuration":67,"studyType":68,"phases":7,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":38,"whyStopped":7,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Fondazione Ricerca Traslazionale","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Federico FC Cappuzzo, PI","IRCCS Ist. Naz. Tum. Regina Elena","PRINCIPAL_INVESTIGATOR",[14,18],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","+390544285206","federico.cappuzzo@ifo.it",{"name":19,"role":15,"phone":20,"phoneExt":7,"email":21},"Grisel GM Maver Militello, Monitor","0652662724","grisel.mavermilitello@ifo.it",[23,37],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":7},"Istituto Tumori Regina Elena","ENROLLING_BY_INVITATION","Roma","RM","000144","Italy","IT",{"type":32,"coordinates":33},"Point",[34,35],11.10642,44.99364,{"lat":35,"lon":34},{"facility":24,"status":38,"city":26,"state":27,"zip":39,"country":29,"countryCode":30,"cosmosGeoPoint":40,"geoPoint":42,"contacts":43},"RECRUITING","00128",{"type":32,"coordinates":41},[34,35],{"lat":35,"lon":34},[44,46,49],{"name":45,"role":15,"phone":20,"phoneExt":7,"email":21},"Grisel GM Maver Militello, S.C",{"name":47,"role":15,"phone":20,"phoneExt":7,"email":48},"carlo CP Ponzo, S.C","carlo.ponzo@ifo.it",{"name":50,"role":51,"phone":7,"phoneExt":7,"email":7},"Lorenza LL Landi, Dott.ssa","SUB_INVESTIGATOR",{"type":53,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100579369","study-investigating-anti-drug-antibodies-in-nsclc-patients-exposed-to-checkpoint-inhibitors-imb-100579369",false,"NCT06823401","Study Investigating Anti-drug Antibodies in NSCLC Patients Exposed to Checkpoint Inhibitors (IMB)","IMMUNOBLOOD: Perspective Study for the Evaluation of Anti-Inhibitory Checkpoint Antibody Development in Patients Undergoing Immunotherapy","IMB","Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of NSCLC\n* Possibility to obtain blood samples\n* Patient candidate, in any therapy line, for a therapy with any checkpoint inhibitor including single agent pembrolizumab, single agent atezolizumab, single agent nivolumab, single agent durvalumab or combination of nivolumab and ipilimumab\n* Performance status 0-2 (ECOG)\n* Patient compliance to trial procedures\n* Age ≥ 18 years\n* Written informed consent\n\nExclusion Criteria:\n\n* No possibility to obtain blood samples\n* Previous therapy with any checkpoint inhibitor\n* Patient candidate for a therapy with a checkpoint inhibitor in combination with chemotherapy or any other non-checkpoint inhibitors\n* Pregnancy or lactating","ALL","18 Years",{"count":65,"type":66},270,"ESTIMATED","2 Years","OBSERVATIONAL","Non-small cell lung cancer (NSCLC) is one of the leading causes of death in Western countries. Today, a new frontier in the fight against cancer is immunotherapy, a treatment that aims to \"awaken\" the patient's immune system to help it recognize and attack cancer cells.\n\nAmong the various approaches, there is significant focus on therapies that activate T lymphocytes, a type of immune cell, encouraging them to react against the tumor. These treatments have led to important progress and represent a hope for the future.",[71],"NSCLC",[73],"immunotherapy","2026-02-05",{"date":76,"type":77},"2026-02-06","ACTUAL",{"date":79,"type":77},"2021-05-20",{"date":81,"type":66},"2029-12-31",{"name":5,"class":6},2]